Jefferies Financial Group Inc. Purchases Shares of 51,400 Beta Bionics, Inc. $BBNX

Jefferies Financial Group Inc. purchased a new stake in Beta Bionics, Inc. (NASDAQ:BBNX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 51,400 shares of the company’s stock, valued at approximately $1,566,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Eventide Asset Management LLC raised its holdings in shares of Beta Bionics by 0.5% in the 3rd quarter. Eventide Asset Management LLC now owns 4,957,252 shares of the company’s stock valued at $98,500,000 after acquiring an additional 24,901 shares in the last quarter. Farallon Capital Management LLC increased its holdings in shares of Beta Bionics by 2.6% in the 3rd quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock worth $85,718,000 after buying an additional 110,000 shares during the last quarter. Soleus Capital Management L.P. increased its holdings in shares of Beta Bionics by 12.5% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock worth $55,622,000 after buying an additional 424,817 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Beta Bionics by 213.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock worth $44,036,000 after buying an additional 1,509,217 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Beta Bionics by 47.0% in the 3rd quarter. Millennium Management LLC now owns 796,964 shares of the company’s stock worth $15,836,000 after buying an additional 254,766 shares during the last quarter.

Beta Bionics Trading Down 0.8%

Beta Bionics stock opened at $11.63 on Thursday. The firm has a 50-day moving average of $10.66 and a 200-day moving average of $17.83. The firm has a market cap of $518.23 million, a P/E ratio of -7.70 and a beta of 3.29. Beta Bionics, Inc. has a 1-year low of $8.80 and a 1-year high of $32.71.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. The company had revenue of $27.63 million during the quarter. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. Research analysts forecast that Beta Bionics, Inc. will post -2.19 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. UBS Group raised shares of Beta Bionics to a “strong-buy” rating in a report on Monday, February 9th. Wall Street Zen cut Beta Bionics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Truist Financial cut their price objective on Beta Bionics from $25.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, April 15th. The Goldman Sachs Group cut their price objective on Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Weiss Ratings cut Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Beta Bionics has an average rating of “Moderate Buy” and a consensus price target of $19.73.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.